D. Western Therapeutics Institute, Inc. (TSE: 4576)
Health Care · Biotechnology · JP
¥88.00
+10.00% today · -17.8% 1Y
D. Western Therapeutics Institute, Inc. (TSE: 4576) operates in the Biotechnology industry within the Health Care sector. The company is valued at $31.86M and employs 19 people.
Over the last twelve months the share price has lost 17.8%, trading between 66.00 and 181.00.
Tweenvest scores D. Western Therapeutics Institute, Inc. across four factors: quality 36/100, value 38/100, growth 0/100. Its strongest factor is value.
4576 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $31.86M
- Revenue (TTM)
- $1.52M
- P/E
- —
- EPS
- -11.97
- Dividend yield
- —
- Beta (5Y)
- -0.00
- 52-week high
- ¥181.00
- 52-week low
- ¥66.00
- Avg volume (3M)
- —
- Shares outstanding
- 57.55M
- Employees
- 19
- Next earnings
- —
About D. Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
- ISIN
- JP3548740004
- Founded
- 1999
- Listed since
- Oct 23, 2009
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | 0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.53 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.11 | +1.60% |
Figures last refreshed Aug 18, 2026.